Literature DB >> 12051462

Epidemiology and current treatment of multiple sclerosis in Europe today.

Carlo Pozzilli1, Silvia Romano, Stefania Cannoni.   

Abstract

Multiple sclerosis (MS) is a chronic disease affecting the central nervous system, usually leading to early disablement in young adults. At least 350,000 persons in Europe have the disease. Wide variations exist both between and within European countries in the incidence and prevalence of the disease as well as in the general standard of care for MS patients. The needs, well-being, and social participation of people with MS are systematically influenced by their physical and cultural environment and the nature of the community services. Moreover, the rate of introduction of the new disease-modifying therapy also widely differs from country to country. This article helps clinical researchers to understand better the differences in epidemiology and in the current treatment of MS in Europe.

Entities:  

Mesh:

Year:  2002        PMID: 12051462

Source DB:  PubMed          Journal:  J Rehabil Res Dev        ISSN: 0748-7711


  4 in total

1.  Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain.

Authors:  Carole Dembek; Leigh Ann White; Jayson Quach; Andrea Szkurhan; Nazia Rashid; M R Blasco
Journal:  Eur J Health Econ       Date:  2013-04-25

2.  Oxidative stress in a model of toxic demyelination in rat brain: the effect of piracetam and vinpocetine.

Authors:  Omar M E Abdel-Salam; Yasser A Khadrawy; Neveen A Salem; Amany A Sleem
Journal:  Neurochem Res       Date:  2011-03-30       Impact factor: 3.996

Review 3.  Exercise therapy for multiple sclerosis.

Authors:  M B Rietberg; D Brooks; B M J Uitdehaag; G Kwakkel
Journal:  Cochrane Database Syst Rev       Date:  2005-01-25

4.  Cortical atrophy is relevant in multiple sclerosis at clinical onset.

Authors:  Massimiliano Calabrese; Matteo Atzori; Valentina Bernardi; Aldo Morra; Chiara Romualdi; Luciano Rinaldi; Matthew J M McAuliffe; Luigi Barachino; Paola Perini; Bruce Fischl; Leontino Battistin; Paolo Gallo
Journal:  J Neurol       Date:  2007-03-14       Impact factor: 4.849

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.